The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Adjuvant treatment of colon cancer: three vs six months of FOLFOX/CAPOX
Alberto Sobrero, MD, Ospedale San Martino, Genova, Italy, discusses the final results from the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration study. This study evaluated overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
